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Abstract
Background: An understanding of the needs and behaviors of asthma patients is important in
developing an asthma-related healthcare policy. The primary goal of the present review was to
assess patient perspectives on key issues in asthma and its management, as captured in patient
surveys.
Methods: Local, national, and multinational asthma surveys were reviewed to assess patient
perspectives, and where possible healthcare provider (HCP) perspectives, on key issues, including
diagnosis, treatment, control, quality of life, and other patient-centered outcomes. Twenty-four
surveys, conducted or published between 1997 and 2003 in Europe and North America, were
included in this review. Substantial differences among studies prevented a formal meta-analysis;
instead, data were pooled to allow for general comparisons and qualitative analysis.
Results: The results indicate that patients' knowledge of the underlying causes of asthma and
treatment options remains inadequate. Moreover, patients often tolerate poor symptom control,
possess meager knowledge of correct drug usage, and display insufficient adherence to therapy.
Many patients have a low expectation of receiving an appropriate therapy or of having a positive
encounter with the HCP. Among HCPs, there is evidence of inadequate understanding of disease
etiology and poor or unstructured communication with patients, resulting often in inaccurate
assessment of disease severity. Moreover, patients often underreport their symptoms and severity,
which in turn could lead to misclassification and undertreatment.
Conclusion: Improving patient education about the importance of achieving optimal asthma
control, along with improved communication between patients and HCPs, emphasizing treatment
options and optimal treatment of inflammation, may lead to better outcomes and improved asthma
management in daily practice.
Background
Asthma is a chronic, inflammatory condition of the air-
ways characterized by airway hyperresponsiveness and
episodic respiratory symptoms, such as breathlessness,
wheezing, chest tightness, and coughing. The prevalence
of asthma continues to increase in many countries: the
current estimate of 300 million people with asthma
worldwide is expected to increase by 33% to 400 million
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by 2025 [1,2]. In addition to the economic burden of
asthma, which is considerable, there are physical, emo-
tional, and social effects, leading to reduced quality of life
(QoL) of patients and their families [3-6].
International surveys have been valuable for understand-
ing and managing asthma. The International Study of
Asthma and Allergies in Childhood, the European Com-
munity Respiratory Health Survey, and other surveys have
provided much needed information on the global pat-
terns of asthma prevalence from childhood to adulthood,
and have generated new hypotheses for further testing and
validation [2,7-10]. An understanding of the needs and
behaviors of asthma patients is also important in develop-
ing asthma-related healthcare policy. The primary goal of
the present review was to assess patient perspectives on
key issues in asthma and its management, including diag-
nosis, treatment, control, and QoL, as captured in patient
surveys in Europe and North America. Where available in
the same surveys, healthcare provider (HCP) perspectives
on a number of key issues in asthma and its management
were assessed. We have attempted to draw conclusions
that are relevant and useful to asthma caregivers.
Methods
A review of asthma patient surveys in Europe and North
America, conducted or published between 1997 and
2003, was undertaken by a general multibased literature
search using keywords that included 'asthma' and 'survey';
additional searches were performed on key authors'
names. The following initial selection criteria were used:
observational/experimental survey design, patient-
reported outcomes, perceptions or data related to asthma
management, and physician-reported aspects of asthma
management. From a total of 68 surveys initially screened,
24 surveys (including some substudies of special popula-
tions) and analyses were ultimately selected to provide a
balanced data pool across a broad range of issues [6,7,11-
32]. These included published and unpublished surveys
translated from local language when necessary. Unpub-
lished surveys were also provided by the sponsor of this
project when there was evidence that they might be rele-
vant, and surveys that were not formally published were
supplemented with data on file provided by the sponsor.
Some surveys were later excluded if data were not ulti-
mately relevant to the core emergent patterns and ques-
tions of the review.
Data from all studies were extracted in a systematic fash-
ion into a large two-dimensional matrix. This approach
simplified identification of subsets of surveys in which the
methods, including design, populations, and outcomes,
were sufficiently similar for possible pooled analysis. The
following main criteria were used to structure the matrix:
the period of data collection, the nature of data extraction
(interview/self-reported questionnaire), questionnaire
type (standardized/nonstandardized), location, study
objectives, design (cross-sectional/longitudinal), the
length of follow-up (if applicable), the sampling method,
sample composition and size, the assessment of asthma
severity, the types of medication used, the assessment of
relevant outcomes, and population demographics.
After the 'extraction phase,' appropriate data were selected
and grouped together to strengthen the outcomes meas-
ured ('pooling phase'). Key criteria such as the design and
sample base were used to group together relevant surveys
so as to address the most important outcomes and the
incidence of those outcomes (expressed as ranges). At this
stage it was clear that substantial differences in studies –
which included differences in national or international
scope, design, setting, timing, sample bases, and objec-
tives – precluded a formal meta-analysis. Thus, while it
was statistically inappropriate to combine results from
these surveys, general comparisons were carefully under-
taken where there were no confounding factors. A list and
overview of the design of surveys reviewed is provided in
Table 1.
The review was further classified according to a structured
set of most relevant outcomes identified ('assessment
phase'). The following patient outcomes were assessed:
understanding of the disease (etiology), perception of
asthma control, satisfaction with treatment, compliance
with therapy, and impact on patient and family QoL.
Childhood asthma was examined separately to identify
any trends specific to this population, although pediatric
data were also included in the wider patient perspective
assessment. At the HCP level, the same outcomes that
were assessed in patients were evaluated when available;
this allowed for a comparison of similarities and differ-
ences in perception between HCPs and patients on these
issues.
Results
The 24 surveys reviewed included a total of 66,450 sub-
jects from a total of 24 countries; of this number, 57,817
were patients (including 11,875 children, generally classi-
fied as <16 years, and parents of children) and 8,633 were
HCPs [6,7,11-32]. Table 1 presents the names of these sur-
veys, together with patient numbers and other descriptors.
Table 2 provides a summary of the sample populations
contained in these surveys. Table 3 summarizes the gen-
eral findings from the survey review.
Asthma understanding and control – the patient 
perspective
Understanding the causes and nature of asthma
A few surveys contained feedback from patients that
addressed their disease understanding. In TARGET [11],BMC Pulmonary Medicine 2006, 6(Suppl 1):S2
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38% of patients or parents considered allergy, and 26%
airway inflammation, as important to asthma, while 60%
were able to specifically name an anti-inflammatory drug
and 22% understood that such therapy was needed to
reduce or control inflammation associated with their
asthma. In a Spanish survey [14], 41% of parents or car-
egivers were able to distinguish asthma symptoms from
those of other respiratory diseases such as bronchitis.
Asthma symptoms, and their control and prevention
Eight surveys [6,11,17,22,24,25,27,32] that collectively
included over 15,000 patients provided the core data
demonstrating the high levels of symptoms reported by
patients, even though they were all receiving asthma ther-
apy. Diurnal symptoms were reported by 46–75% and
nocturnal symptoms by 30–70% of the patients in three
studies [6,11,22]. Patients often appeared to tolerate high
Table 1: Overall scope and dimension of the surveys
Study name Country Objective Population Design Date
MORI/EFA [12] France, Germany, Great 
Britain, Italy, Spain
Family QoL impact Parents Face-to-face interview. International 
comparison
1999–2002
TARGET [11] Italy Symptoms, causes, 
treatment
HCPs, parents Face-to-face interviews, with physicians 
and patients (adults and children). 
Advisory board-driven
2002
AIRLife [13] Germany Efficacy/patient 
preferences
HCPs, parents Telephone interviews with physicians and 
adult patients. Face-to-face interviews 
with asthmatic children and parents of 
asthmatic children
1999
National Paediatric 
Asthma [14]
Spain Attitudes/QoL Parents of young children Face-to-face interviews with parents of 
children with asthma (aged 2–5 years)
2000
ASTHMA [6] Belgium +/- montelukast GP/parents GPs interviewed asthma patients before 
and then at least 4 weeks after treatment 
with montelukast
2001
ASTEQ/ASTHMA [15] France Symptoms while using 
ICS. Perception of control
Prescribers/patients/
(children in subset)
Anonymous questionnaire of physicians 
and patients including a small pediatric 
substudy conducted at 20 asthma schools 
with 300 children (aged 2–14)
1999/2003
NOP/GPnet [16] Great Britain BTS guidelines impact GPs/nurses/parents Postal questionnaire, GPs, nurses and 
parents of children with asthma
2002
UK AIR [17] Great Britain Asthma control GPs/nurses/children/
parents
Questionnaire of patients, telephone 
interviews with practice nurses, face-to-
face interviews of GPs
1997
Finnish AIR [18] Finland Asthma control GPs/nurses/adult patients/
children/parents
Postal questionnaire 2000
Danish AIR [19] Denmark Reality asthma control (2 
year)
Patients Postal questionnaire 2000–2002
Norwegian AIR [20] Norway Reality asthma control Patients/GPs Postal questionnaire of patients, 
telephone interview of GPs
2000–2001
ALMA [21] Sweden Reality asthma control Patients/GPs Telephone interviews with adult asthma 
patients. Questionnaire for GPs with 
similar questions
2000–2001
AIRE [22] France, Great Britain, 
Italy, Germany, 
Netherlands, Spain, 
Sweden
How are treatment 
guidelines truly being 
applied/perceptions
Patients/children Telephone interviews with adult asthma 
patients (randomly selected)
1999
ECRHS [7] 14 countries (including 
Canada)
Follow up on asthma 
development and use of 
services
Patients Administered questionnaire 1990–2000
ECRHSII [23] 10 EU countries Perception of severity, 
impact on society
Patients Telephone interviews (randomly 
selected). Advisory-board driven
1999
Living and Breathing [24] UK Symptoms/control Patients Face-to-face interviews 2001
RESPONSE [25] Germany, Spain, Great 
Britain
True symptom control, 
QoL, drug use
Adults/juveniles Face-to-face interviews 2001
ACE [26] UK Treatment (ICS) benefit 
perceptions
Patients at pharmacies Face-to-face interviews 2002
Asthma in America [27] USA Asthma in USA (misc.) Adults, HCPs (physicians, 
nurses, pharmacists)
Telephone interviews (randomly 
selected)
2001
Asthma [28] Finland National impact snapshot Patients Review 1998
Psychology/Health and 
Medicine [29]
Sweden Comparing assessment 
methodologies
Patients Questionnaire-based survey 2003
AJN [30] USA Assessment/outcome 
tools
Children/parents Review 2002
Illness Management 
Survey [31]
USA Barriers to juvenile 
treatment (questionnaire 
support)
Juveniles Questionnaire-based survey. Focus on 
compliance in highly noncompliant subset
2003
HUNAIR [32] Hungary Cost, morbidity, control Children/adults Questionnaire-based survey 1998–1999
AIR, Asthma In Real Life; BTS, British Thoracic Society; ECRHS, European Community Respiratory Health Survey; EU, European
Union; GP, general practitioner; HCP, healthcare provider; ICS, inhaled corticosteroids; QoL, quality of life.BMC Pulmonary Medicine 2006, 6(Suppl 1):S2
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levels of symptoms, often understating the severity of
their disease (Figure 1). In three European studies
[11,24,25], while a large proportion of patients reported
daily symptoms, a greater proportion considered their
symptoms under control, and very few considered their
disease 'out of control.' One survey reported that a major-
ity of pediatric patients or their parents (65%) considered
their asthma well controlled despite a high incidence of
breathing difficulties (37%), sleep disturbances (34%),
dry cough (29%), and difficulty talking (29%) at least
once weekly because of their asthma [17].
Perhaps not surprisingly, some surveys provided data to
indicate a poor level of control while others indicated a
high level of suboptimal therapy. One survey, comparing
treatments across Europe, discovered a complete absence
of treatment in <20% to 70% of patients from country to
country (70% in Estonia) [23]. In a US survey, only 20%
of 2,509 symptomatic patients were found to be using
anti-inflammatory therapy (mainly inhaled corticoster-
oids (ICS)), even though at least 23% of these patients
had undergone hospitalization or urgent care during the
previous year [27]. In surveys where anti-inflammatory
treatment was specified, ICS were commonly used,
although in a highly variable range (15–92%). Only 4%
of 347 parents of children with asthma in one survey [16]
had heard of alternative anti-inflammatory treatments.
There was also some evidence for incomplete patient
understanding of treatments, with one pan-European sur-
vey reporting that, when asked about the definition of
controller therapy, an average of 26% of parents of chil-
dren with asthma gave markedly incorrect responses [12].
Expectations and satisfaction
Eighteen surveys, with a combined patient population of
approximately 34,000, reported data on patient satisfac-
tion and were pooled for descriptive analysis [6,11,13-
17,19-28,32]. Many studies touched on the issue of expec-
tations and satisfaction, sometimes in an oblique way
[6,13,15-17,19-22,27]. The general inference from these
studies was that large numbers of patients had a low level
of satisfaction regarding their contacts with HCPs, and
that there was often a low level of patient expectation
from therapy. At least two studies showed that optimal
therapy is more often provided when patient-physician
contact is more frequent and more structured [15,23].
Adherence to therapy
Fourteen surveys [6,11-21,26,27] that included approxi-
mately 28,300 patients illustrated various adherence
issues. A number of patients admitted underuse of their
medication (at least 40%) either in terms of frequency or
dosing [12,13,15,17-21,26,27]. In several surveys, 40–
70% of patients admitted that one factor in their lack of
adherence was high discomfort with long-term use of ICS
[11,13,14,32]. This was reflected in the observation that
approximately one-third of patients reported dissatisfac-
tion with long-term ICS treatment [26]. When patients
were prescribed higher doses of ICS by their physicians to
regain control, at least 50% refused to adhere to their pre-
scribed therapy fully because of concerns over side effects
[13].
Impact on lifestyle
Eleven surveys that included approximately 34,700
patients assessed varied lifestyle-related endpoints [6,12-
15,17-19,25,27,32]. Overall, these varied data suggest
that asthma has a much understated impact on lifestyle
and QoL.
Although one survey showed that lifestyle was affected
irrespective of disease severity [26], overall the surveys
suggested a relationship between severity of disease and
QoL. There was some anecdotal indication that, subject to
the severity of disease, incomplete control of inflamma-
tion and therefore lack of control of asthma symptoms
were associated with significantly reduced QoL in patients
[6,15,27].
Asthma and children
Fifteen surveys [6,11-18,22,25,27,30-32] allowed evalua-
tion of asthma in 8,384 children, some by survey of car-
egivers. Findings were consistent with those of adult
populations, raising particular concerns about high levels
of symptoms, dissatisfaction with treatment, impact on
lifestyle, concerns related to side effects of treatment, poor
compliance, and missed school or work (Table 4).
Survey contributions by the healthcare provider
Over 8,600 HCPs were included in the surveys reviewed
[6,11,16,27,29,30]. Of particular interest was the observa-
tion that detailed understanding of asthma pathophysiol-
ogy, and therefore appropriate treatment, was perhaps
limited. In the TARGET survey [11], 59% of 305 physi-
cians believed that allergic factors were dominant in the
etiology of asthma, and only 35% (and only 16% of pedi-
Table 2: Study populations in the reviewed surveys
Number Percentage
Patients (adults) 45,942 69.1
Patients (children)
Children (including juveniles) 2,820 4.2
Parents representing children 9,055 13.6
Healthcare providers
General practitioners 4,925 7.4
Specialists 3,202 4.8
Nurses 393 0.6
Pharmacists 113 0.2
Total 66,450 100BMC Pulmonary Medicine 2006, 6(Suppl 1):S2
Page 5 of 9
(page number not for citation purposes)
Table 3: Summary of key review findings
Subthemes Core findings Key supporting data
Patient perceptions Understanding of disease In general, patients (or caregiver) lack 
knowledge of their asthma and its causes
Only 22% thought asthma therapy reduced 
inflammation [11]
Patients are aware of asthma symptoms, but 
are often willing to tolerate poor control or 
are unaware of the risks
92% of patients experienced limitations of activities 
due to asthma, and 48% had difficulty with sleeping [6]
Despite poor control, many patients still 
describe themselves as 'well controlled'
>65% had symptoms during the last week, although 
>80% considered themselves to be 'under control' [25]
Symptom control Inappropriate use of available drugs may 
contribute to poor control
21.3% and 26.4% of patients with 'some' and 'severe' 
control limitations, respectively, actually used anti-
inflammatory drugs [27]
More aggressive anti-inflammatory treatment 
can improve control
Addition of a secondary anti-inflammatory agent 
(LTRA) improved sleep (87% of patients), early waking 
(80%), daily functionality (85%), and need for rescue 
medication (77%) [6]
Patients often do not realize asthma drugs 
have side effects
61% of parents of children with asthma did not realize 
inhaled corticosteroids had side effects [16]
Patient satisfaction Patient satisfaction with their treatment is low In general, these figures are understatements and 
inference gives higher possibilities
Patient satisfaction (and participation) with 
their management is often low
28% of patients did not tell their physician in 
consultation about troublesome coughing, and 36% 
failed to mention difficulty in sleeping [15]
Admitted compliance with treatment is often 
poor, expressed both by lack of as well as 
excessive use of prescribed treatment
45% of patients admitted using their medication 
excessively [19]
Compliance Patients cited steroid use as a major reasons 
for lack of compliance
One-third of patients expressed dissatisfaction with 
long-term steroid treatment [26]
Lifestyle issues for patients and family Control Lack of control was mentioned as being 
associated with reduced QoL in a number of 
surveys
General comment
Disease severity Correlation between QoL and disease severity 
was suggested
General comment
True impact The impact of asthma on QoL is often 
understated
General comment
Lifestyle restrictions Patients reported substantial lifestyle 
restrictions
Irrespective of disease severity, approximately 70% 
report substantial lifestyle restrictions [26]
Families The QoL of families of children with asthma is 
also clearly affected
20% of parents stated that their work attendance was 
affected, and 50% said their own lives were affected 
[14]
Child specific Management Generally children are better managed than 
adults despite some parental reservations 
about disease
Asthmatic children are significantly greater consumers 
of resources than asthmatic adults, despite having 
better initial asthma control [32]
Perceptions As in adult asthmatics, there is a marked 
difference between perception and reality of 
symptom control in children (or by their 
caregivers)
65% of children with asthma or their carers considered 
their asthma to be well controlled, although 37% had 
difficulty breathing, 34% had nocturnal waking, 29% had 
dry cough, and the ability to talk was affected in 29% at 
least once weekly [17]
Therapy understanding Parental understanding of their child's 
medication (and compliance) can also be poor
33% of parents of asthmatic children did not 
understand the role of 'controller' versus 'preventer' 
therapies, and only 38% of parents took their 
controller medication on a regular basis [12]
Treatment needs There seems to be a particular demand for 
better treatments for children
70% of parents of asthmatic children were concerned 
about the effects of inhaled corticosteroids [11]
Healthcare providers Etiology Some HCPs do not fully understand some of 
the recent advances in the understanding of 
asthma etiology
59% of physicians questioned considered allergy the 
main cause of asthma, with only 35% (and only 16% of 
pediatricians) citing the underlying inflammation. In the 
same survey, however, 92% of physicians understood 
that leukotrienes were important mediators of 
inflammation in asthma [11]
Treatment needs Some of the surveys examined physicians' 
inconsistent use of anti-inflammatory agents in 
asthma among the suboptimal numbers of 
patients actually being treated
92% of physicians considered anti-inflammatory drugs 
'essential' in asthma care, although only 20% of patients 
were receiving these agents [27]
Diagnosis There was practical support for the need for 
improved diagnosis of asthma leading to 
improved management
The utility of decision-making tools and self-reporting 
questionnaires for assessing disease severity and 
optimizing therapy can measure and improve 
treatment compliance [31]
Similarities and differences between 
HCPs and patients
Similarities In most relevant studies, patients and HCPs 
generally agreed that better treatments with 
fewer side effects would be desirable
General comment
Substantial differences HCPs and patients disagreed over symptom 
control
Only 1% of patients considered themselves symptom 
free, compared with 24% of their general practitioners 
[21]
HCPs and patients disagreed over compliance 
levels
HCPs believed that 'all' of their patients complied with 
treatment, whereas only 60% of patients actually did 
according to HCP definition [20]
HCPs and patients disagreed over concern 
towards side-effects
General comment
HCP, healthcare provider; LTRA, leukotriene receptor antagonist; QoL, quality of life.BMC Pulmonary Medicine 2006, 6(Suppl 1):S2
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atricians) cited underlying airway inflammation. In
another survey [27], physicians reported that an average
of only 20% of their asthma patients were actually pre-
scribed an anti-inflammatory product (of which 73%
received ICS) – usually only after persistent asthmasymp-
toms during the previous month, and in particular only
after an acute event.
Of broad interest was the attitude towards using contin-
ued or increased doses of ICS compared with newer ther-
apies. Again, in the TARGET survey [11], although 98% of
physicians agreed that it was important to treat inflamma-
tion in asthma, ICS were rarely prescribed for periods of
greater than 6 months.
Comparisons of views between patients and healthcare 
providers
Patients reporting symptoms of asthma often reported
that their asthma was well controlled, while in combined
patient/HCP surveys their HCP reported that it was not
well controlled [13,17,20,21]. Conflicting data, however,
were also seen: 1% of patients, as opposed to 7% of their
physicians, considered their asthma to be very severe; this
contrasted with 1% of patients considering themselves
completely free from symptoms, while 24% of the HCPs
who assessed them thought the same [21]. In another sur-
vey [20], patients were more likely than their physicians to
regard their disease as more serious and life-threatening.
In the UK Asthma In Real Life study [17], HCPs were also
found to underestimate the impact of asthma symptoms
on their patients, perhaps as a consequence of patients'
willingness to tolerate fairly severe symptoms and associ-
ated lifestyle restrictions (with 65% of patients consider-
ing themselves to have well-controlled disease despite the
high incidence of severe symptoms) and thus not raising
them with their HCPs. This survey also found that HCPs
underestimated patients' need for relief inhalers. Patients
appear to also underreport their incidence of side effects
from drugs; for example, direct consultation with 240
patients with asthma also showed they experienced a
higher incidence of side effects than their physicians real-
ized [21].
Patient perceptions of asthma control and symptom frequency Figure 1
Patient perceptions of asthma control and symptom frequency. Percentages of all patients in three UK studies 
[17,24,25] who considered their asthma to be controlled or well controlled and percentages of patients in those three studies 
who were experiencing asthma symptoms or using a rescue β2-agonist. *In the UK Asthma treatment needs study, symptoms 
were reported ≥3 times per week. **For the UK pediatric Asthma In Real Life (AIR) study, the symptom reported is difficulty 
breathing. †For the UK pediatric AIR study, the β2-agonist use reported is two or more times per day. ‡For the UK pediatric 
AIR study, the β2-agonist use reported is one or more times per day.
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There was a greater agreement in the views of patients and
HCPs relating to long-term therapy. In one survey [11],
57% of physicians reported that their patients were reluc-
tant to take corticosteroids long term and their patients
agreed: almost 50% and 70% were apprehensive about
taking ICS and oral corticosteroids, respectively, generally
because of concern over long-term side effects associated
with these drugs. In another survey [13], 59% of physi-
cians and 53% of patients were worried about long-term
use of corticosteroids, regardless of disease severity.
Discussion
The present review of 24 patient surveys indicates that
patients often experience high levels of asthma symptoms
even while receiving asthma therapy. Patients' perceptions
of asthma control and prevalence of symptoms were often
mismatched: patients who considered their asthma well
controlled still reported daily symptoms. Furthermore,
while many patients were conscious of the clinical factors
indicative of lack of symptom control (coughing, breath-
lessness, and sleep disturbances), many failed to fully
understand the impact of the disease on their everyday
life, and patient awareness did not necessarily translate
into an understanding of the need to control symptoms.
A substantial majority of patients appeared to tolerate
suboptimal treatment. In addition, the survey results sug-
gest that asthma may have a substantially underestimated
impact on QoL, expressed in terms of difficulty in breath-
ing, ability to exercise, and quality of sleep.
Adherence failure was common because of a variety of fac-
tors and not just because of concerns about drug side
effects. This was often compounded by a low expectation
of receiving an appropriate therapy or of having a positive
encounter with the HCP. Surprisingly, physicians were
also often unaware of the extent of their patients' poor
adherence or misuse of treatments. Moreover, patients
often underreported their symptoms and severity, which
in turn could have led to misclassification and undertreat-
ment.
Overall, the results of the present review indicate that
many patients lack an understanding of the importance of
inflammation in asthma, and few are aware of the anti-
inflammatory effects of treatments. A recent review of the
Asthma Insights and Reality surveys referred to the low
level of use of anti-inflammatory medication, the subop-
timal control of asthma, and the consequent deterioration
in the lifestyle of patients [33]. These results reinforce the
need for renewed efforts to effectively inform patients,
both through and apart from their HCP. Such general
patient-awareness education should emphasize not only
the inflammatory etiology of asthma and the importance
of appropriate treatment, but also aspects of improved
patient self-diagnosis, awareness of additional treatment
choices that could further modify disease progression,
and also the implications of treatment, such as drug side
effects.
Overall, pediatric patients seemed to be better managed
than adults with asthma, not simply because there tends
Table 4: Issues in childhood asthma
Issues Findings
Symptoms and resource use • Children achieve a better level of symptom control than adults, and use more healthcare resources 
[32]
• 72% of parents reported their children having experienced a serious asthma event [14]
Understanding of asthma and its treatment • Only 41% of parents referred to their child's disease as 'asthma' [14]
• 33% of parents of asthmatic children did not understand the terms 'controller' or 'preventer' therapy 
[12]
Impact on the life of children and family • 21% of children had missed school within previous 3 months [12]
• 36% of children had limitations on physical activities [12]
• 6% of parents had missed work within previous 3 months [12]
• 20% of parents believed their children are treated badly at school [14]
• 50% of parents believed their lives were affected by their child's asthma [14]
Adherence • Only 38% of parents stated that their children used controller medication regularly [12]
• Juveniles presented particular adherence issues, showing reluctance to use inhalers in the presence 
of others [13]
• In juveniles, specific decision-making tools for professionals as well as parents are helpful in 
identifying true severity and optimizing management [30]
• Customized self-reported questionnaires can help identify potential noncompliance in juveniles 
before this became a major issue [31]
Concerns about treatments • 70% of parents were concerned about their children using inhaled corticosteroids [11]
• 33% of parents specified a desire for convenient nonsteroid treatments [14]
• 66% of parents would switch their child's therapy if possible because of concerns about side effects 
of current drugs [14]BMC Pulmonary Medicine 2006, 6(Suppl 1):S2
Page 8 of 9
(page number not for citation purposes)
to be a stronger emphasis on childhood asthma in most
countries, but also because caregivers and parents seemed
to show greater involvement in managing their children's
disease and were highly conscious of drug safety issues.
The surveys did, however, highlight parents' confusion
about, and their lack of understanding of, childhood
asthma and its therapies. A number of parents (approxi-
mately 40%) in one survey regarded asthma in their chil-
dren as a stigma and were in potential denial of their
children's condition [14]. This clearly represents an
opportunity for further patient and caregiver education.
As with the adult populations, there was a strong differ-
ence between perception of control (by children and their
caregivers) and the practical issues of symptom manage-
ment. In general, children utilized a proportionately
greater share of resources than adults [32]. A recent review
of epidemiological surveys and clinical studies of asthma
in children [34] reports evidence of poor asthma control
in children: only a small proportion of children world-
wide attain the goals of good asthma control as set out by
the Global Initiative for Asthma [35,36].
A common theme that emerges from many of the surveys
is the dissatisfaction and poor outcomes seen with asthma
controller medications. Among the numerous reasons for
this are concerns over safety, poor efficacy, and poor
adherence. Encouragingly, both patients and their HCPs
generally seemed to agree within the same survey that
there was a need to use medications with fewer side effects
and fewer long-term complications. There was, however,
some evidence of differences in opinion among physi-
cians on the best strategy for long-term and more com-
plete asthma control.
Our report evaluates asthma management from the
patients' perspective. The 24 surveys reviewed illustrate
the burden of asthma in patients and attitudes toward its
diagnosis and treatment among patients as well as HCPs,
including asthma specialists, pediatricians, general practi-
tioners, pharmacists, and nurses. A limitation of the
present review is therefore that it constituted a qualitative
analysis and hence could be considered a subjective
appraisal. A true quantitative meta-analysis was not possi-
ble because of the variety in study designs, as well as in
populations and outcomes studied. Moreover, the selec-
tion of studies was not fully comprehensive; instead, we
chose to include a varied selection of surveys to provide as
balanced a perspective as possible. The surveys originated
in many different countries in Europe and North America
and were conducted by different sponsors, including three
different pharmaceutical companies. Nevertheless, we
believe some important and consistent messages emerge
that should influence better asthma management in the
future.
Conclusion
Findings of the present review of asthma surveys suggest
that patients often understate their symptoms, tolerate
poor symptom control, have low expectations of therapy,
possess meager knowledge of correct drug usage, and dis-
play insufficient adherence to therapy. Among HCPs,
there is evidence of an inadequate understanding of dis-
ease etiology and poor or unstructured communication
with patients, resulting often in inaccurate assessment of
disease severity. With the increasing incidence of asthma,
it is important to address these many issues as a matter of
priority. In particular, asthma care could be made sub-
stantially better by improving the education of patients
regarding the nature of the disease (as one primarily of
inflammation) and optimizing the use of existing medical
systems and treatments.
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